Stocks to Watch:Vodafone Group Plc (ADR) (NASDAQ:VOD), Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)

On Thursday, Shares of Vodafone Group Plc (ADR) (NASDAQ:VOD), subtract -3.29% and closed at $26.48 in the last trading session. The last trading range of the stock ranges between $26.31 and $26.85. The company’s Market capitalization is $69.26 Billion with the total Outstanding Shares of 26.56 billion. Vodafone Group Plc operates as a telecommunications company worldwide. The company offers voice, messaging, and data services across mobile and fixed networks; broadband and TV services; cloud and hosting, in addition to Internet protocol-virtual private network services; roaming services; and unified communications services. It also provides M-Pesa, a mobile money transfer and payment service; and Vodafone One, an ultra-high-speed fixed broadband service with Ono Fibre, home landline, 4G mobile telephony, and Vodafone TV. In addition, Vodafone Group Plc offers Internet of Things (IoT), which is communication between devices via mobile technologies; international voice transit and roaming; carrier services, such as fixed and mobile connectivity and other services; and smartphones and tablets.

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $26.31 and reached to max level of $34.70. The EPS of company is strolling at -1.87.

Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), dropped 2.97% and closed at $11.77 in the last trading session. The last trading range of the stock ranges between $11.48 and $12.13. The company’s Market capitalization is $2.80 Billion with the total Outstanding Shares of 194.20 million. ARIAD Pharmaceuticals, Inc. (ARIA) recently declared clinical data on its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, were published in The Lancet Oncology (Gettinger, S.; ed al. The Lancet Onc. 2016, DOI: 10.1016/S1470-2045(16)30392-8 Published 8 November 2016). ARIAD has presented a New Drug Application (NDA) for brigatinib to the U.S. Food and Drug Administration (FDA), seeking U.S. marketing approval for patients with metastatic ALK-positive (ALK+) non-small cell lung cancer (NSCLC) who are resistant or intolerant to crizotinib.

“The publication reports the results of the first clinical evaluation of brigatinib in patients with advanced malignancies, counting ALK+ NSCLC,” stated Scott N. Gettinger, M.D., associate professor of medicine at Yale Cancer Center and lead author. “Brigatinib yielded responses in the majority of patients with crizotinib-treated ALK+ NSCLC, with median progression free survival of over one year. In Addition To, responses in the brain were achieved in this crizotinib refractory population. Early onset pulmonary adverse events, which occurred in eight percent of patients, generally within 48 hours of first dose, appeared to be related to starting dose.”

Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $4.37 and reached to max level of $14.34. The EPS of company is strolling at -0.18.

Leave a Reply

Your email address will not be published. Required fields are marked *